Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD B POWELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1023103702
CMS profile
819362
Location
NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$39.93

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $39.93 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Vanda Pharmaceuticals Inc. $28.82 1
Amarin Pharma Inc. $11.11 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD B POWELL

NPI 1023103702 · CMS profile ID 819362

Allopathic & Osteopathic Physicians / Internal Medicine

NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $39.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $28.8206/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735141111 CMS
Amarin Pharma Inc. $11.1101/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740008645 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,998.99 5
PY2020 $39.93 2
PY2023 $3,086.41 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,379.85 19
PY2024 Principal investigator $519,613.32 181
PY2023 Principal investigator $3,705,517.67 2,390
PY2022 Principal investigator $2,801,811.98 590
PY2021 Principal investigator $422,228.81 39
PY2020 Principal investigator $83,061.46 21
PY2019 Principal investigator $408,254.19 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,200.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
CIMRD005476 No dispute reported 06/30/2026 844035561
Principal investigator 1 Janssen Pharmaceuticals, Inc $840.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576587
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,380.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576607
Principal investigator 1 Janssen Research & Development, LLC $101,366.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839189
Principal investigator 1 PFIZER INC. $17,334.00 12/22/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832541341
Principal investigator 1 PFIZER INC. $10,833.75 12/07/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832540133
Principal investigator 1 PFIZER INC. $14,000.50 11/23/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832642717
Principal investigator 1 Janssen Pharmaceuticals, Inc $588.00 11/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576577
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,106.00 11/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576597
Principal investigator 1 Janssen Research & Development, LLC $42,164.00 11/17/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838647
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,162.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787577095
Principal investigator 1 Janssen Research & Development, LLC $6,720.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839088
Principal investigator 1 Janssen Research & Development, LLC $30,048.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839101
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,260.00 10/13/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787577085
Principal investigator 1 Janssen Research & Development, LLC $4,334.00 09/27/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838252
Principal investigator 1 Janssen Research & Development, LLC $26,232.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838207
Principal investigator 1 PFIZER INC. $10,820.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 832591489
Principal investigator 1 PFIZER INC. $14,000.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832641625
Principal investigator 1 Janssen Research & Development, LLC $7,040.00 09/17/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838263
Principal investigator 1 PFIZER INC. $6,800.00 09/04/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832879963
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,900.00 08/25/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576095
Principal investigator 1 Janssen Research & Development, LLC $27,135.00 08/25/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838239
Principal investigator 1 Janssen Research & Development, LLC $47,040.00 08/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838223
Principal investigator 1 Noven Pharmaceuticals, Inc. $2.40 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831012143
Principal investigator 1 Noven Pharmaceuticals, Inc. $82.05 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831012227
Principal investigator 1 Noven Pharmaceuticals, Inc. $0.99 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831012497
Principal investigator 1 Noven Pharmaceuticals, Inc. $54.70 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831012619
Principal investigator 1 Noven Pharmaceuticals, Inc. $2.58 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831012813
Principal investigator 1 Noven Pharmaceuticals, Inc. $27.25 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831013061
Principal investigator 1 Noven Pharmaceuticals, Inc. $149.28 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831013221
Principal investigator 1 Noven Pharmaceuticals, Inc. $27.25 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831013393
Principal investigator 1 Noven Pharmaceuticals, Inc. $100.96 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831013427
Principal investigator 1 Noven Pharmaceuticals, Inc. $100.96 07/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831013461
Principal investigator 1 PFIZER INC. $2,555.88 04/21/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832832925
Principal investigator 1 PFIZER INC. $662.50 03/24/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832713095
Principal investigator 1 Noven Pharmaceuticals, Inc. $1,500.00 03/22/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee No dispute reported 06/30/2026 831011125
Principal investigator 1 Novartis Pharmaceuticals Corporation $280.00 03/01/2021 Non-covered Recipient Entity
NEW HORIZONS CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS No dispute reported 06/30/2026 800637795
Principal investigator 1 PFIZER INC. $1,358.13 02/05/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832792415
Principal investigator 1 PFIZER INC. $2,020.63 01/12/2021 Non-covered Recipient Entity
Velocity Clinical Research Cincinnati
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832826877